Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Y90 IBRITUMOMAB RX (OTHER 1111000826) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 17, 2026 , from http://ppman.hank.ai/transparency/procedure/1111000826/by-state?code_type=OTHER
“Y90 IBRITUMOMAB RX (OTHER 1111000826) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/1111000826/by-state?code_type=OTHER. Accessed
October 17, 2026 .
“Y90 IBRITUMOMAB RX (OTHER 1111000826) by State,” HANK Price Transparency ,
accessed October 17, 2026 ,
http://ppman.hank.ai/transparency/procedure/1111000826/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
1111000826 — Y90 Ibritumomab Rx
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$76,026
National median
$68,424 – $76,473
IQR (p25 – p75)
15
hospitals filing
2
states
Walking in without insurance?
Cash / self-pay price
Cash median
$60,374
vs. negotiated
-20.6%
Hospitals reporting
15
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 1111000826 (OTHER), with interquartile range
State Median p25 p75
ID $76,473 $76,473 $76,473
UT $73,343 $68,424 $76,473